Professional
Added to YB: 2025-05-09
Pitch date: 2025-05-05
LQDA [neutral]
Liquidia Corporation
+119.06%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Market Cap
$3.3B
Pitch Price
$16.00
Price Target
50.00 (+43%)
Dividend
N/A
EV/EBITDA
-32.09
P/E
-26.30
EV/Sales
48.61
Sector
Pharmaceuticals
Category
special_situation
Buckley Capital Portfolio Holding: Liquidia Corporation
LQDA (holding update): Yutrepia dry powder inhaler for PAH/PH-ILD superior to UTHR's products. After winning patent litigation vs UTHR, launching May 2025. Could take 50%+ of growing market. Bought $4-5 in 2022, expect double in 2025 + triple in future years with $50+ target. Acquisition potential within 2 years.
Read full article (2 min)